R744 + R744

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Peritoneal Dialysis Patients

Conditions

Peritoneal Dialysis Patients

Trial Timeline

Feb 1, 2007 → Nov 1, 2008

NCT ID

NCT00433849

About R744 + R744

R744 + R744 is a phase 3 stage product being developed by Chugai Pharmaceutical for Peritoneal Dialysis Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT00433849. Target conditions include Peritoneal Dialysis Patients.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00433849	Phase 3	Completed	Feb 1, 2007	Nov 1, 2008	Peritoneal Dialysis Patients
NCT00433615	Phase 3	Completed	Feb 1, 2007	Nov 1, 2008	Anemia in Pre-Dialysis Patients
NCT00433888	Phase 3	Completed	Jan 1, 2007	Oct 1, 2008	Hemodialysis Patients

Competing Products

20 competing products in Peritoneal Dialysis Patients

See all competitors

Product	Company	Stage	Hype Score
azenosertib	Zentalis Pharmaceuticals	Phase 2	44
MCY-M11 + Cyclophosphamide	MaxCyte	Phase 1	25
roxadustat	Astellas Pharma	Phase 3	77
Abemaciclib	Eli Lilly	Phase 1	33
M200 (Volociximab) + Liposomal Doxorubicin + M200 (Volociximab) + M200 (Volociximab)	AbbVie	Phase 1/2	41
Adavosertib + Paclitaxel + Carboplatin + Gemcitabine + PLD	AstraZeneca	Phase 2	52
Tremelimumab + Olaparib	AstraZeneca	Phase 1	33
ertapenem	Merck	Approved	85
Octreotide LAR + Octreotide (Immediate release) + methylprednisolone + Placebo	Novartis	Phase 2	52
PA21	Kissei Pharmaceutical	Phase 3	76
PF-06873600 + Endocrine Therapy 1 + Endocrine Therapy 2	Pfizer	Phase 1/2	40
Bevacizumab + Nivolumab + Rucaparib	Bristol Myers Squibb	Phase 2	51
Iniparib	Sanofi	Phase 2	51
Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )	Sanofi	Phase 3	76
nanoliposomal irinotecan	Ipsen	Phase 1	30
Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution	Baxter	Approved	82
Anti-Adhesion Product	Baxter	Phase 2	49
Pioglitazone	Baxter	Pre-clinical	20
Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solution	Baxter	Approved	82
Radspherin	Oncoinvent	Phase 2	44

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved

Pegasys® + Pegasys®Approved

ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3

R744 + Epoetin betaPhase 3

EmicizumabPhase 3